Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MME
REST API REST API
Homo sapiens
MME is differentially expressed in 307 experiments: 140 organism parts: kidney, adipose tissue, ... (138 more);, 210 disease states: normal, prostate carcinoma, ... (208 more);, 103 cell types 493 cell lines 23 compound treatments and 72 other conditions.
Synonyms NEP, CALLA, CD10
Orthologs Q67BJ2_CHICK (Gallus gallus)   Mme (Mus musculus)   MME (Bos taurus)   Mme (Rattus norvegicus)   Nep1 (Drosophila melanogaster)   Nep4 (Drosophila melanogaster)   mme (Xenopus laevis)   MME (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, protein binding, axon, peptide metabolic process, metalloendopeptidase activity, membrane, metallopeptidase activity, peptidase activity, metal ion binding, cell-cell signaling, membrane fraction, synaptic vesicle, peptide binding, integral to plasma membrane, dendrite, synapse, proteolysis, beta-amyloid metabolic process, neuron projection terminus
InterPro Term Peptidase_M13_C, Peptidase_M13_N
UniProt Accession C9J9X7, C9IYX7, Q3KQS6, C9JDZ3, P08473, C9JR96
Search EB-eye ENSG00000196549
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-GEOD-7540, E-GEOD-3526, E-MTAB-62, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, ... (42 experiments)

Factor Value U/D Experiments
SW480
3
E-MEXP-1014, E-GEOD-2509, E-MTAB-37
BT474
2
E-MTAB-37, E-MTAB-62
AGS
2
E-GEOD-15460, E-MTAB-37
LNCaP
2
E-GEOD-14464, E-GEOD-14990
MCF-10A
2
E-TABM-420, E-GEOD-14990
MOLT4
2
E-MTAB-37, E-MTAB-62
487 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-20677, E-GEOD-21750, E-GEOD-21909, ... (50 experiments)

Factor Value U/D Experiments
CD8+ T cell
2
E-MTAB-25, E-AFMX-5
centroblast
2
E-TABM-702, E-GEOD-15271
embryonic stem cell
2
E-GEOD-2248, E-MEXP-930
human embryonic stem cell
2
E-GEOD-18265, E-GEOD-20033
whole blood
2
E-GEOD-3026, E-MTAB-25
mesenchymal stem cell
1
2
E-MEXP-466, E-GEOD-2248, E-GEOD-9894
97 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-GEOD-1577, ... (70 experiments)

Factor Value U/D Experiments
prostate carcinoma
1
4
E-MTAB-62, E-MEXP-2034, E-GEOD-7307, E-MEXP-1327, E-TABM-26 ... (5 experiments)
lung adenocarcinoma
1
3
E-GEOD-2514, E-MEXP-231, E-MTAB-62, E-MTAB-37
gastric carcinoma
2
E-MTAB-37, E-GEOD-2685
sarcoma
2
E-MTAB-62, E-MTAB-37
Wilms tumor
2
E-GEOD-2712, E-MTAB-37
acute promyelocytic leukemia
2
E-GEOD-995, E-MTAB-62
204 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-15205, E-GEOD-5741, E-GEOD-3356, E-MEXP-2590, ... (15 experiments)

Factor Value U/D Experiments
none
4
E-GEOD-995, E-GEOD-2322, E-MEXP-2285, E-GEOD-412
ethanol
2
E-MEXP-2241, E-GEOD-3113
5-aza-2'-deoxycytidine + trichostatin A
2
1
E-MEXP-1269
nebivolol
1
E-GEOD-3356
ponasterone A
1
E-GEOD-3113
TGF
1
E-GEOD-15205
17 more value(s).


Age at diagnosis

studied in E-GEOD-3494, E-GEOD-4922

Factor Value U/D Experiments
34 years
1
1
E-GEOD-4922
34
2
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-2191, E-GEOD-19246, ... (11 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-20033, E-MEXP-2359, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-22544, E-GEOD-3325, E-GEOD-1561, ... (10 experiments)

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MTAB-73, E-GEOD-7578, E-GEOD-20847, E-MTAB-108, E-MEXP-563 ... (5 experiments)

Genotype
studied in E-GEOD-22056, E-TABM-36, E-GEOD-2466, E-GEOD-17476, E-MEXP-421, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-2657, E-GEOD-20540, E-GEOD-22278, E-GEOD-837, ... (15 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-974, E-MEXP-2069, E-GEOD-1926, ... (35 experiments)

Infection
studied in E-GEOD-12108, E-MEXP-561

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-12662

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-22152, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, ... (7 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-3254, E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-MEXP-1422, E-GEOD-12438, E-MEXP-101, E-GEOD-3697, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

Sex
studied in E-GEOD-3320, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815 ... (5 experiments)

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-3494

Tumor size
studied in E-GEOD-3494

Processing time: 0.349 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM